Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI Australia ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.8 (market cap $4.49B), while iShares MSCI Australia ETF trades at $28.04. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | EWA | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $30.26 |
52-Week Low | $20.06 | $24.95 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EWA trades at $28.33, up 0.85% on the day, with technical indicators showing a bearish trend in moving averages and mixed signals from oscillators. The stock faces resistance near $29 and support at $28. Recent news highlights Australian economic headwinds, including missed GDP growth and regulatory changes affecting banks and property markets, which may influence EWA's performance given its exposure to Australian equities.
The outlook for EWA is cautious due to bearish technicals and macroeconomic pressures in Australia. Risks include slower economic growth and sector-specific challenges, but potential opportunities exist if market sentiment improves or if dividend policies attract income-focused investors. Investors should weigh these factors against the current neutral-to-bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
